New immunotherapy shows promise in slowing deadly brain cancer
Disease control
Ongoing
This study tests an experimental immunotherapy called IGV-001 in people newly diagnosed with glioblastoma, an aggressive brain cancer. The treatment uses a patient's own cells to target the cancer and is compared to a placebo. The goal is to see if it can slow tumor growth and he…
Phase: PHASE2 • Sponsor: Imvax • Aim: Disease control
Last updated May 08, 2026 12:01 UTC